Purpose of review Mantle cell lymphoma (MCL) is a mature B-cell malignancy that continues to have a high mortality rate. In this article, we discuss key pathogenic pathways in MCL biology and their possible therapeutic targeting.
INTRODUCTION
Mantle cell lymphoma (MCL) is a mature CD5þ B-cell neoplasm accounting for $6% of nonHodgkin's lymphomas (NHL) that contributes disproportionately to NHL-related mortality. MCL presents as a disseminated disease, with a leukemic component in $20-30% of cases, and frequent involvement of the gastrointestinal tract. Its hallmark translocation t(11;14)(q13;q32) puts the cyclin-D1 gene (CCND1) in close proximity of the immunoglobulin heavy locus (IGH) resulting in cyclin-D1 overexpression [1, 2] . No single genetic lesion that can give rise to MCL has been identified. The cyclin-D1 translocation is usually accompanied by additional genetic alterations affecting cell cycle, survival pathways and DNA damage response. A relatively high degree of genomic instability characterizes MCL among B-cell NHL, and may contribute to its clinical and biological heterogeneity [2, 3 && ]. The neural transcription factor SOX11 is expressed in most cases of MCL [4, 5] . Recent data show that SOX11 regulates PAX5 expression, and its knockdown induces a shift toward plasmacytic differentiation. Thus, SOX11 may prevent maturation of MCL cells and play a role in the pathogenesis. Silencing SOX11 in MCL cell lines resulted in a slower tumor growth in xenograft models [6 && ]. Treatment of MCL represents a challenge. Despite a high response rate to first-line chemotherapy, the majority of patients relapses and succumbs to their disease. Even patients having remissions lasting beyond 5 years are not free of disease recurrence, as late relapses are well documented [7, 8] .
Because of the relatively low incidence of MCL, comparative trials have been rare, and no clear standard of care has been established [9] . Intensive combination of cytotoxic drugs followed by consolidation with high-dose chemotherapy and autologous stem cell transplantation has been widely adopted for young and fit patients (recently reviewed in [7, 8] ). However, the only potentially curative approach remains allogeneic stem cell transplantation. The high response rate with intensive regimens is typically achieved at the expense of increased toxicity and a significant risk of treatment-related death, preventing their use in the frail and elderly who represent more than 50% of patients [9] . Moreover, a recent retrospective study reported that the survival benefit achieved by intensive chemotherapy over conventional treatment is lost when adjusted for clinical risk factors [10] . Unlike other B-cell NHL, single-agent rituximab has limited activity in MCL, and using rituximab in combination with chemotherapy added only a modest benefit compared with chemotherapy alone [11] .
Here, we discuss recent advances in MCL biology, with a particular focus on pathways critical for disease pathogenesis, and tumor proliferation and survival. In particular, we will discuss cyclin-D1 and cell cycle control, DNA damage response, the B-cell receptor (BCR) and nuclear factor-kappa B (NFkB) pathways, tumor-microenvironment interactions and finally B-cell lymphoma 2 (BCL-2) and resistance to apoptosis (Fig. 1) . These pathways may constitute the Achilles heel of MCL, offering the prospect of targeted treatment approaches.
CYCLIN-D1
Cyclin-D1 overexpression plays a central role in MCL biology [2] . In addition to t(11;14)(q13;q32), cyclin-D1 levels may be increased due to deletions or point mutations in the 3' untranslated region that produces relatively shorter and more stable mRNAs [12, 13] . High cyclin-D1 mRNA levels correlate with increased tumor proliferation and inferior survival. Variable levels of cyclin-D2 and cyclin-D3 are also reported in MCL cell lines, and cyclin-D1 knockdown resulted in minimal cytotoxicity possibly due to compensatory upregulation of cyclin-D2 [14] . Further, cyclin-D1-negative MCL exists that expresses the other D-type cyclins, cyclin-D2 or cyclin-D3, indicating that D-type cyclins may have redundant functions in MCL biology.
D-type cyclins dimerize with cyclin-dependent kinase4 (CDK4) and CDK6 to phosphorylate retinoblastoma (Rb) proteins, thus promoting G1/S transition and cell cycle entry (Fig. 1) . In addition, cyclin-D1/CDK4 complexes bind and titrate the cell cycle inhibitors p27 and p21 away from cyclin-E/CDK2 complexes, further enhancing cell cycle progression. Moreover, CDK4 and CDK6 activity in MCL can be enhanced through loss of their inhibitor, p16, secondary to CDKN2A (encodes p16) deletion or BMI-1 (transcriptional repressor of CDKN2A) amplification. Alvocidib (flavopiridol) is a pan-CDK inhibitor that also blocks RNA synthesis by inhibiting the CDK9/cyclin-T complex. The modest clinical activity of alvocidib has been linked to its complex pharmacokinetics [15] . Palbociclib (PD-0332991) is a reversible, specific inhibitor of CDK4 that is orally bioavailable and well tolerated in early studies. Seventeen relapsed MCLs were treated in a phase I trial with 125 mg of palbociclib administered daily for 21 days of 28-day cycles [16] . The overall response rate (ORR) was 18%, including one complete response (CR) ( Table 1) [16] [17] [18] [19] [20] [21] . Reduction in phospho-Rb and Ki67 was observed in most patients but did not predict response duration.
Palbociclib induces early G1 arrest (pG1), and withdrawal results in S phase entry. Thus, sequenced administration of palbociclib could be used to synchronize tumor proliferation and sensitize tumor cells to pG1-specific or S-specific-targeted/cytotoxic agents [22 & ]. This strategy is currently being tested by combining palbociclib with bortezomib [23] .
THE ROLE OF B-CELL RECEPTOR SIGNALING AND THE TISSUE MICROENVIRONMENT IN MANTLE CELL LYMPHOMA
The tumor microenvironment plays an important role in many B-cell malignancies [24, 25] . Similar to chronic lymphocytic leukemia (CLL), MCL typically involves blood, bone marrow, spleen and lymph
KEY POINTS
The BCR signaling pathway and microenvironment support play an important role in MCL biology.
The BTK inhibitor ibrutinib induces high and durable responses in previously treated MCL (ORR 68% and mPFS 13.9 months), and is now US Food and Drug Administration approved for this indication.
Activation of the noncanonical NIK-NFkB pathway in MCL represents a possible mechanism of resistance to ibrutinib.
Selective PI3Kd inhibition induces short-lived responses possibly because of compensatory upregulation of other PI3K isoforms.
The BCL-2 selective inhibitor ABT-199 is highly active, and spares BCL-X L resulting in less thrombocytopenia.
The high degree of genomic instability makes MCL vulnerable to 'synthetic lethal' approaches through inhibition of DNA repair mechanisms.
nodes. In addition, MCL shows a propensity to involve gastrointestinal, oropharyngeal and pulmonary sites as well as the skin. Interestingly, the primary site of disease presentation has some prognostic information, suggesting that different tissue tropism correlates with differences in disease biology [26] . A dependence on prosurvival factors in the tissue is supported by experiments demonstrating that coculture of MCL cells with stromal cells extends their survival in vitro and can protect them from the cytotoxic effects of chemotherapy [27] . In addition, we recently showed that MCL cells in the lymph node show activation of the BCR and NFkB pathways and are more proliferative than their counterparts in the peripheral blood [28] .
MCL is often considered a transformation of pregerminal center B-cells that are antigen-naive. However, analysis of the clonal IGHV gene suggests cIAP2) and TRAF2 release NIK from the inhibition, which leads to noncanonical NFkB pathway activation. Upon activation by apoptotic stimuli, the BH3-only proteins (e.g. BIM and BAD) inhibit the antiapoptotic BCL-2 family members (e.g. BCL-2 and BCL-X L ), thus releasing the proapoptotic members BAX and BAK and inducing apoptosis through caspase activation. Cyclin-D1 dimerizes with CDK4 and CDK6 to phosphorylate the Rb protein, thus releasing the transcription factor E2F and promoting cell cycle entry. Upon DNA damage, ATM activates P53 to initiate DNA repair, cell cycle inhibition or even cell death. CHK1 and CHK2 kinases activate P53, whereas MDM2 and MDM4 E3-ubiquitin ligases inhibit P53. Illustration by authors. BCR, B-cell receptor; CDK, cyclin-dependent kinase; MCL, mantle cell lymphoma; NFkB, nuclear factor-kappa B; NIK, NFkB-inducing kinase.
that most MCL cells have undergone some antigen selection. Further, a subset of MCL shows evidence of early plasmacytic differentiation [29] . The IGHV gene encodes the immunoglobulin (Ig) heavy chain variable region that is responsible in part for binding to antigen. In a recent study of 807 MCL samples, Hadzidimitriou et al. [30] showed that the IGHV repertoire is biased toward frequent usage of IGHV3 and IGHV4 subsets. Moreover, up to 40% of tumors expressed IGHV genes with somatic hypermutation, a characteristic of postgerminal B-cells indicating antigen selection. Further, it is not uncommon to encounter different MCL patients with virtually identical BCRs, so-called stereotyped BCRs, suggesting exposure to the same antigen [30] . Akin to CLL, MCL tumors expressing mutated IGHV genes tend to have a somewhat more indolent course, albeit with less pronounced differences in outcome than that seen in CLL [4] . These data suggest that in MCL as in CLL antigen selection plays an important role in disease biology [25] . This point is underscored by the observation that the BCR on MCL cells is activated in vivo and this activation, as previously shown for CLL [31] , is primarily located to the lymph node [28] . The BCR comprises a transmembrane Ig with an extracellular antigen-binding domain, and an intracellular signaling domain linked to two coreceptors: Iga (CD79A) and Igb (CD79B). Upon antigen binding, the BCR signals through a series of kinases, including Lck/Yes novel tyrosine kinase, spleen tyrosine kinase (SYK), phosphatidylinositol 3-kinase delta (PI3Kd) and Bruton's tyrosine kinase (BTK) among others (Fig. 1) . A recent study reported that primary unmanipulated MCL cells have higher levels of p-NFkB and p-AKT compared with normal B-cells, and phosphorylation of SYK and PLCg in response to BCR activation was more pronounced compared with normal B-cells and other NHL. Further, BCR-induced levels of p-SYK correlated with the degree of CD79B expression [32] .
Among the different BCR pathway kinases, SYK, PI3Kd and BTK are of particular importance as they are essential for BCR signaling and normal B-cell development. SYK is sometimes amplified in MCL leading to SYK mRNA and protein overexpression [2] . PI3Kd is the most abundant PI3K isoform expressed in MCL. However, PI3Ka and PI3Kg isoforms are also expressed, and PI3Ka is often amplified. PI3K downstream of SYK is responsible for phosphorylating AKT and mammalian target of rapamycin (mTOR). Increased PI3K/AKT/mTOR signaling can be achieved through enhanced SYK phosphorylation or loss of the phosphatase and tensin homolog phosphatase [33] . Loss of function mutations in BTK results in X-linked agammaglobulinemia, an immunodeficiency syndrome characterized by the absence of mature B-cells. BTK is also expressed in neutrophils, monocytes, macrophages and platelets, but not in T-lymphocytes or plasma cells; its role in these cells remains unclear. BTK is required for BCR-mediated survival signals, and inhibition of BTK can induce apoptosis of tumor cells from several B-cell malignancies, including MCL, CLL and diffuse large B-cell lymphoma [34] [35] [36] . Moreover, BTK is overexpressed in MCL when compared with normal B-cells [35] [43, 44] . So, it will be interesting to see whether these drugs lead to more sustained and durable responses.
Ibrutinib, a first-in-class, orally bioavailable, covalent inhibitor of BTK, has recently shown striking clinical activity in many relapsed/refractory B-cell NHL [37 && ,39]. Ibrutinib binds covalently to Cys-481 on BTK and thereby irreversibly inactivates the kinase. A limited number of kinases possess a comparable cysteine residue, which confers considerable selectivity to ibrutinib. In a recent phase II trial, Wang et al. [19 && ] treated 111 relapsed/refractory MCL patients with 560 mg of ibrutinib once daily. Ibrutinib was overall well tolerated. The ORR was 68% (CR, 21%), median progression-free survival was 13.9 months, and overall survival was 58% at 18 months (Table 1) . On the basis of these data, the US Food and Drug Administration granted accelerated approval to ibrutinib for relapsed/refractory MCL in November 2013. However, 32% of patients did not respond to ibrutinib, and 50% progressed within 14 months of therapy, respectively, suggesting both intrinsic and acquired mechanisms of resistance. Rahal et al. [45 && ] reported on intrinsic resistance to ibrutinib in six of 10 MCL cell lines. BCR pathway target genes and CARD11 were overexpressed in sensitive cells, and treatment with 
B-CELL LYMPHOMA 2
The apoptosis regulator BCL-2 family of proteins consists of antiapoptotic members (e.g. BCL-2, MCL-1, BCL-W and BCL-X L ) and proapoptotic members (e.g. BAX, BAK, BIM and BAD) (Fig. 1) . Upregulation of BCL-2, MCL-1 and BCL-X L , and inactivation of BIM through genomic deletion, have been described in MCL [1] . Targeting prosurvival members of the BCL-2 family represents a promising approach to restore the apoptotic balance. Navitoclax (ABT-263) is an orally bioavailable molecule that targets both BCL-2 and BCL-X L . Navitoclax has shown encouraging results in early-phase clinical trials; however, it was associated with a dose-limiting, concentration-dependent, rapid and profound thrombocytopenia, secondary to BCL-X L inhibition [46, 47] . This prompted an effort to reengineer into a BCL-2 selective molecule that spares BCL-X L [48] . The resultant ABT-199 (GDC-0199) is an orally bioavailable, first-in-class BCL-2 selective inhibitor. The high selectivity of ABT-199 for BCL-2 allows higher, more effective drug concentrations without thrombocytopenia [48, 49] . Davids et al. [20] treated a cohort of relapsed/refractory NHL with single-agent ABT-199 in a phase I, dose-escalation trial. Thirty-two patients were enrolled, eight of whom had MCL. The drug was overall well tolerated, and only two patients discontinued the drug due to G3/4 neutropenia. G3/4 thrombocytopenia occurred in 13% of patients, but was not dosedependent or dose-limiting. All MCL patients responded to therapy (ORR 100%) across the different dosing regimens. All responders had partial response (Table 1) . Dose escalation is still ongoing to determine the maximum tolerated dose for phase II. Touzeau et al. [50] showed that not all MCL cell lines are sensitive to ABT-199, and that microenvironment support through CD40 signaling can protect MCL cells against ABT-199. Thus, to unlock the full potential of ABT-199 it may be necessary to combine it with agents that can inhibit the prosurvival effects of the tissue microenvironment, such as ibrutinib or PI3K inhibitors [51, 52] .
DNA DAMAGE RESPONSE
In addition to cyclin-D1 overexpression, the high degree of genomic instability represents a classic feature of MCL. These frequent recurrent genetic aberrations include losses, gains and copy number amplifications [1, 2] . Interestingly, MCL does not appear to carry a higher burden of somatic mutations than other B-cell malignancies [3 && ,53]. The reason remains unclear, but may be in part explained by increased stability of the DNA replication factor, CDT1, secondary to increased cyclin-D1/CDK4 AAK, Aurora-A kinase; BCL-2, B-cell lymphoma 2; BTK, Bruton's tyrosine kinase; CDK4/CDK6, cyclin-dependent kinase 4/6; CR, complete remission; MCL, mantle cell lymphoma; mDOR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; mTOR, mammalian target of rapamycin; N/A, not available; ORR, overall response rate; PI3Kd, phosphatidylinositol 3-kinase delta.
activity, resulting in aberrant reinitiation of DNA replication during S phase [2] . The tumor suppressor ATM is the most commonly mutated gene in MCL, and also may be lost through the recurrent 11q22-23 deletion. ATM plays a critical role in DNA repair in response to double-strand breaks (DSBs). Lymphoid cells need to undergo ordered DSBs to allow Ig rearrangements. Starczynski et al. [54] characterized different NHL subtypes and normal B-cells at different stages of differentiation for ATM expression. They found high levels of ATM in B-cells of the mantle zone and in plasma cells, but low levels in germinal center B-cells and in immature B-cells of the bone marrow. ATM levels in NHL subtypes mirror their cells of origin; low ATM levels were observed in most follicular lymphoma and diffuse large B-cell lymphoma, and ATM deletion or inactivating mutations were absent. In contrast, tumors originating from pregerminal and postgerminal center B-cells showed high ATM expression in the absence of ATM inactivating lesions, but these tumors displayed an increasing frequency of ATM inactivating mutations or deletion. Indeed, MCL has a higher frequency of ATM alterations compared with other NHL. This pressure to lose ATM in MCL may derive from the high ATM level in the cell of origin, and can be further enhanced by the high frequency of DSBs due to inappropriate reinitiation of DNA replication.
ATM functions in the DNA damage response pathway by activating P53 (Fig. 1) . In turn, P53 may be inactivated by 17p deletion and TP53 mutations [3 && ]. P53 function can also be affected by loss of CDKN2A locus that encodes the P53 stabilizer ARF, overexpression of the P53 inhibitors MDM2 and MDM4 and downregulation of the P53 activators CHK1 and CHK2. Further, UBR5, an E3 ubiquitin ligase required for effective CHK2 phosphorylation and subsequent P53 activation, is mutated in 18% of MCL tumors [55 && ]. UBR5 also plays a critical role in the response to DNA DSBs [56] . Interestingly, UBR5 and CCND1 mutations were reported to be mutually exclusive in a cohort of 102 patients [54] , whereas other mutations often coexist in the same tumor sample.
The degree of genomic instability and the high frequency of ATM and TP53 alterations may constitute an Achilles heel that can be exploited for 'synthetic lethal' therapeutic approaches. Two genes are synthetic lethal if mutation of either alone is compatible with viability but mutation of both leads to death [57] . Thus, in the context of drug therapy of a tumor carrying a mutated gene, cell death may be achieved by inhibiting a synthetic lethal gene. The extensive alterations in the DNA damage response found in MCL can lead to 'mitotic catastrophe', the destruction of the cell during mitosis secondary to extensive DNA damage and/or defects in chromosome segregation. The Poly-ADP ribose polymerase (PARP) is a critical enzyme involved in DNA repair for which small molecule inhibitors have been developed. ATM deficiency sensitizes MCL cell lines in vitro and in vivo to PARP inhibition, and this sensitivity is enhanced in the presence of a concomitant P53 deficiency [58] . Combining PARP inhibitors with DNA damaging agents may further increase the therapeutic effect [59] .
Another enzyme important for successful mitosis is Aurora-A kinase (AAK), a serine/threonine kinase essential for centrosome maturation and separation. AAK is overexpressed in MCL and linked to inferior outcomes. AAK inhibition results in G2/M arrest, accumulation of mitotic cells, polyploidy and subsequent cell death. Alisertib (MLN-8237) is an oral, selective, adenosine triphosphate-competitive reversible inhibitor of AAK. A phase II study of alisertib in 48 NHL reported an ORR of 23% in the MCL group (three of 13), with one CR (Table  1 ). The most common G3/4 adverse events were hematologic [21] . Alisertib synergizes in vitro and in vivo with the microtubule inhibitor vincristine against MCL, and rituximab enhances this synergism [60] . The combination of the three drugs was found to be safe and effective in a phase I study of relapsed/refractory NHL [61] .
CONCLUSION
Identifying the specific vulnerabilities of cancer cells, it is hoped, can be used to develop targeted therapies. In some cases, disease-specific, genetic driver events have led the way. One of the most prominent and successful examples is chronic myelogenous leukemia. In contrast, MCL is a more heterogeneous disease, and a clear oncogenic driver remains elusive. The recent approval of ibrutinib for relapsed MCL constitutes an important milestone that in large part appears to have arisen from systematic clinical investigation. A number of new-targeted drugs have entered clinical trials. Moving forward, incorporating the increasingly powerful genomic tools into clinical investigation may reveal the Achilles heel of MCL and will guide the most effective use of these agents.
